All News

Found 47 articles

• Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment

  1/27/2022

  Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).

• 14th Annual Biotech Showcase™ Brings Together One of The Largest, Most Informative Biotech Investment Conferences Virtually

  1/20/2022

  In its 14th year, Biotech Showcase™, co-produced by Demy-Colton and EBD Group, welcomed over 2,400 attendees, nearly a 10 percent increase from last year, together with over 860 investors, and 320 presenting companies.

• ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment

  1/7/2022

  ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on Jan. 11, 2022 from 8 AM to 9 AM PST.

• Cognito Therapeutics Appoints Jennifer Newberger as Head of Regulatory and Compliance

  12/14/2021

  Cognito Therapeutics announced today the appointment of Jennifer Newberger as Vice President, Head of Regulatory Affairs and Compliance.

• Digital Therapeutics Alliance Elects Cognito Therapeutics’ Everett Crosland to its Board of Directors

  12/8/2021

  Digital Therapeutics Alliance today announced the election of Everett Crosland, Chief Commercial Officer, Cognito Therapeutics to its Board of Directors.

• Cognito Therapeutics CEO Brent Vaughan to Speak at CODE Conference 2021

  9/15/2021

  Cognito Therapeutics announced today its CEO Brent Vaughan will speak at CODE Conference , in Beverly Hills, CA, September 27-29, 2021 to discuss Cognito’s ground-breaking technology that has shown the promise of slowing or stopping the progression of Alzheimer’s and its potential to fundamentally expand human cognitive performance.

• Cognito Therapeutics Announces Formation of Payor Advisory Board

  9/8/2021

  Cognito Therapeutics announced today the formation of a first-in-category Payor Advisory Board to enable day one payor coverage upon approval and insure timely and broad patient access to Cognito’s breakthrough treatment for Alzheimer’s.

• Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021

  8/4/2021

  Cognito Therapeutics today announced that Brent Vaughan, CEO, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 11:00-11:25 am ET.

• 

  Clinical Catch-Up: July 26-30

  8/2/2021

  With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look.
• 

  Alzheimer's Association Annual Meeting Starts with Plenty of Exciting Data

  7/26/2021

  Today is the first day of the Alzheimer’s Association International Conference 2021 (AAIC), behind held both virtually and in person in Denver, Colorado. Here’s a look at some of today’s stories.

• Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

  7/26/2021

  Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma F requency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

• Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021

  7/14/2021

  Cognito Therapeutics today announced the acceptance of six research abstracts at the Alzheimer’s Association International Conference ® 2021 (AAIC ® ) .

• Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board

  7/6/2021

  Cognito Therapeutics today announced the appointment of Gerald Chan, ScD. as Chairman of the Board.

• Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease

  6/14/2021

  Cognito Therapeutics, announced today its plans to add a second digital therapeutic to the company’s pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimer’s Disease (DS-AD).

• Cognito Therapeutics Appoints Everett Crosland as Chief Commercial Officer

  5/18/2021

  Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of Everett Crosland as Chief Commercial Officer.

• Cognito Therapeutics Appoints Jonathan Lieber as Chief Financial Officer

  5/5/2021

  Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of Jonathan Lieber as Chief Financial Officer.

• Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021

  3/17/2021

  Cognito Therapeutics, a clinical-stage company developing a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today that it will advance its lead product which has received FDA Breakthrough Device Designation, into pivotal studies in the second half of this year, based on results from two clinical studies announced at the Alzheimer’s Disease Parkinson’s Disease Conference (AD/PD) 2021.

• Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease

  3/9/2021

  Phase 2 data reported at 2021 AD/PD Conference showed gamma frequency neuromodulation was safe and well tolerated Over the 6-month period, patients in the treatment group exhibited a significant 84% slowing of functional decline in ADCS-ADL scores as well as a significant 83% slowing in memory and cognitive decline as measured by MMSE scores compared to placebo/sham

• Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference

  3/2/2021

  Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today it will present for the first time, new clinical data for its digital therapeutic utilizing gamma frequency neuromodulation in Alzheimer’s Disease, at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), held virtually March 9-14, 2021.

• Cognito Therapeutics Appoints Mark Day, Ph.D., as Chief Business Officer

  1/27/2021

  Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of Mark Day, Ph.D., as Chief Business Officer.